Physician profile
Michael J Styler
NPI 1568402469
$1,201.37
in general payments reported to CMS, 2019-2025
19 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $22.23 · 2021: $112 · 2022: $116 · 2023: $128 · 2024: $421 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $331.12 | 2020-2025 | Vanflyta, Injectafer |
| Janssen Biotech, INC. | $134.85 | 2019-2024 | Tecvayli, Darzalex, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $121.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $106.29 | 2021-2025 | |
| Kite Pharma, INC. | $100.30 | 2024 | Yescarta |
| Astellas Pharma US INC | $99.00 | 2022 | |
| Adaptive Biotechnologies Corporation | $66.96 | 2025 | Clonoseq |
| Genentech, INC. | $59.32 | 2024 | Columvi |
| Pharmacyclics LLC, An Abbvie Company | $29.77 | 2023 | Imbruvica |
| Abbvie INC. | $26.08 | 2023 | Epkinly |
| Eisai INC. | $22.85 | 2025 | |
| Genmab U.S., INC. | $21.90 | 2024 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $19.36 | 2019 | |
| Amgen INC. | $17.29 | 2022 | |
| Glaxosmithkline, LLC. | $17.09 | 2024 | Ojjaara |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eusa Pharma (US) LLC | $15.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.53 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Styler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.